Ahmed Md Selim, Bae Yong-Soo
Department of Biological Science, Sungkyunkwan University, Suwon 16419, Korea.
Immune Netw. 2016 Feb;16(1):44-51. doi: 10.4110/in.2016.16.1.44. Epub 2016 Feb 25.
Dendritic cells (DCs) are professional antigen presenting cells, and play an important role in the induction of antigen-specific adaptive immunity. However, some DC populations are involved in immune regulation and immune tolerance. These DC populations are believed to take part in the control of immune exaggeration and immune disorder, and maintain immune homeostasis in the body. Tolerogenic DCs (tolDCs) can be generated in vitro by genetic or pharmacological modification or by controlling the maturation stages of cytokine-derived DCs. These tolDCs have been investigated for the treatment of rheumatoid arthritis (RA) in experimental animal models. In the last decade, several in vitro and in vivo approaches have been translated into clinical trials. As of 2015, three tolDC trials for RA are on the list of ClinicalTrial.gov (www.clinicaltrials.gov). Other trials for RA are in progress and will be listed soon. In this review, we discuss the evolution of tolDC-based immunotherapy for RA and its limitations and future prospects.
树突状细胞（DCs）是专职抗原呈递细胞，在诱导抗原特异性适应性免疫中发挥重要作用。然而，一些DC群体参与免疫调节和免疫耐受。这些DC群体被认为参与控制免疫亢进和免疫紊乱，并维持体内免疫稳态。耐受性DCs（tolDCs）可通过基因或药物修饰或通过控制细胞因子来源的DCs的成熟阶段在体外产生。在实验动物模型中，已经对这些tolDCs用于治疗类风湿性关节炎（RA）进行了研究。在过去十年中，几种体外和体内方法已转化为临床试验。截至2015年，三项针对RA的tolDC试验已列入ClinicalTrial.gov（www.clinicaltrials.gov）名单。其他针对RA的试验正在进行中，不久将被列入。在本综述中，我们讨论了基于tolDC的RA免疫疗法的发展及其局限性和未来前景。
